Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model

INTRODUCTION: Dual bronchodilators are recommended as maintenance treatment for patients with symptomatic COPD in the UK; further evidence is needed to evaluate cost-effectiveness versus monotherapy. Cost-effectiveness of umeclidinium/vilanterol versus umeclidinium and salmeterol from a UK healthcar...

Descripción completa

Detalles Bibliográficos
Autores principales: Shukla, Soham, Shah, Dhvani, Martin, Alan, Risebrough, Nancy A, Kendall, Robyn, Vogelmeier, Claus F, Boucot, Isabelle, Tombs, Lee, Bjermer, Leif, Jones, Paul W, Kerwin, Edward, Compton, Chris, Maltais, François, Lipson, David A, Ismaila, Afisi S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8668403/
https://www.ncbi.nlm.nih.gov/pubmed/34916789
http://dx.doi.org/10.2147/COPD.S331636

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8668403/
https://www.ncbi.nlm.nih.gov/pubmed/34916789
http://dx.doi.org/10.2147/COPD.S331636

Ejemplares similares